Navigation Links
Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
Date:10/6/2009

DALLAS, Oct. 6 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it had signed an agreement with iMedicor (OTC Bulletin Board: VMCI) for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy. Using iMedicor's highly targeted Alerts System application, initial introduction of MuGard to the 216,000 selected physicians in the US is expected to begin by the end of the year. MuGard is being commercially launched worldwide, with initial launches in the United Kingdom, Germany, Italy, Norway and Greece having been previously announced. Access expects additional commercial launches in Europe, and in the Far East through two partners to start shortly.

"We look forward to working with Access Pharma to help them introduce MuGard in a cost effective, non-intrusive manner, a potential blockbuster product which could significantly improve the quality of life for patients undergoing certain cancer treatments," said Fred Zolla, CEO of Vemics iMedicor. "Using our Alert System, iMedicor's ability to deliver essential information from a trusted source to specific physician audiences will significantly increase our client's marketing ROI."

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ShowerBuddy - Affordable, Accessible Bathing
2. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
3. Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story
4. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
5. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
6. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
7. First U.S. Patients Enrolled in the REALISM Continued Access Study
8. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
9. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
10. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Zimmer Holdings, Inc. ... announced the future executive leadership team and organizational structure ... Biomet transaction.  Zimmer also announced that the combined organization ... will be named Zimmer Biomet, with the new brand ... the closing of the merger.  The future leadership team ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2
... REGN ) today announced that the Company ... agreement (Agreement) with Genentech, Inc., a member of the ... U.S. ophthalmic sales of EYLEA™ (aflibercept) Injection. ... relating to VEGF receptor proteins, known as the Davis-Smyth ...
... testing, the gold standard in hypothyroid diagnosis, may be ... article titled Hormone Replacement Therapy in the ... for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone ... independently written and published, is a broad study of ...
Cached Medicine Technology:Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 2Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 3Studies Show That TSH Is Unreliable in the Diagnosis of Hypothyroidism According to Article Contributed by Kent Holtorf, M.D. in Clinical Geriatrics 2
(Date:10/30/2014)... cancer care respects the fact that a patient,s ... requires treatment. Over a third of cancer patients ... of their conditions. And, increasingly, care providers are ... patients navigate mental health challenges. A University of ... journal Psycho-Oncology asks an important question: ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
(Date:10/29/2014)... certain prostate cancer medications are linked with an increased ... congestive heart failure or prior heart attacks. Published in ... and patients weigh the benefits and risks of the ... levels of male hormones in the body to prevent ... treatment for prostate cancer. Despite its anticancer effects, ADT ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/28/2014)... NY (October 27, 2014)—Although oral hormonal therapy is ... women with hormone receptor–positive tumors, about one-half of ... A study by Columbia University Medical Center (CUMC) ... aromatase inhibitors (the most common type of hormone ... brand-name counterparts, increased treatment adherence by 50 percent. ...
Breaking Medicine News(10 mins):Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Gentle caffeine boost for premature babies 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at high ... detect the deadly skin cancer at an early stage, new ... some people from having a doctor examine their skin for ... Archives of Dermatology . People at high risk for ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... flares of multiple sclerosis (MS), but does not help ... guidelines say. Plasma exchange, or plasmapheresis, is also ... chronic inflammatory demyelinating polyneuropathy and it may be considered ...
... poor can prevent young children from reaching their full genetic potential ... University of Texas at Austin looked at 750 sets of twins ... and 2 years. During the tests the children were asked to ... placing three cubes in a cup, and matching pictures. At ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... called calcium channel blockers face an increased risk of ... shock if they take certain antibiotics, Canadian researchers warn. ... to patients taking calcium channel blockers, can increase the ...
... -- Among middle-school students, friendships can make the difference ... Students whose friends are socially active in positive ways ... badly get lower grades, according to the results of ... also staying away from deviant peers was associated with ...
... surgery remains significantly different when compared to the patient,s opposite ... a study that updated prior findings, researchers used X-rays providing ... relation to the shoulder blade, to compared motion in the ... tendon tears and no symptoms in their other shoulders. An ...
Cached Medicine News:Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 3Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Friends a Big Influence on Grades in Middle School: Study 2Health News:Henry Ford Hospital study: Shoulder function not fully restored after surgery 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers. Polyethylene cover....
Medicine Products: